🔗 Share this article

As America proceeds with unprecedented changes to its immunization guidelines, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccines in the pandemic and has focused upon possible deaths following Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Schedule

Agency leaders planned to unveil sweeping revisions to the childhood immunization program in December, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US at odds with many the international standard with little proof for improved outcomes. The planned update has been pushed back until the coming year.

In place of Vinay Prasad, Høeg is set to speak at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to run the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing some childhood vaccine recommendations in the US in order to be more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – usually the domain of Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Expertise

The appointee has little discernible background in medication creation, approval processes or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Past heads of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that former directors who led CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“Many people just focuses on the new drug program, but the generic program approves numerous generic drugs. There’s a biologic copycat branch, OTC medication office and more, and every single one must be looked after,” Woodcock noted. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management component to the role, which oversees over 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official concluded.

Official Statement and Contentious Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among agency officials on vaccines, a spokesperson said that the “questions stem from flawed presumptions”.

“This background aligns with the duties of her role,” the spokesperson stated, citing the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a controversial rapid drug-approval program that allegedly worried her preceding directors. “How are these drugs being selected for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There is a lot of secrecy happening at the FDA right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of all drugs, aside from immunizations.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, past, some experts observe. She published a research paper using unverified crowd-sourced reports to assess the incidence of heart inflammation following COVID-19 vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership encompassed changing guidelines for new vaccines and ending “unnecessary” vaccines, she stated following the vote on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her beliefs and works backwards to retrofit the science in a highly disingenuous, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|